Interaction between Rhinitis and Asthma: State of the Art

Allergy and Asthma Proceedings

Volumn 24, Issue 6, 2003, Pages 385-393

  Frieri, Marianne ^a  

^a NASSAU UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CETIRIZINE; CORTICOSTEROID; DECONGESTIVE AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LORATADINE; MONTELUKAST; PSEUDOEPHEDRINE; ZAFIRLUKAST;

ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHUS HYPERREACTIVITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG EFFECT; FORCED EXPIRATORY VOLUME; HISTOPATHOLOGY; HUMAN; LUNG LAVAGE; PATHOPHYSIOLOGY; RISK FACTOR; SOCIOECONOMICS; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE ACTIVATION; UPPER RESPIRATORY TRACT;

ADRENAL CORTEX HORMONES; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHIAL HYPERREACTIVITY; HISTAMINE H1 ANTAGONISTS; HUMANS; LEUKOTRIENE ANTAGONISTS; RHINITIS, ALLERGIC, PERENNIAL;

EID: 0942289844     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (84)

1. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 81:478-518, 1998.
2. Nathan RA, Meltzer EO, Selner JC, et al. Prevalence of allergic rhinitis in the United States. J Allergy Clin Immunol 99:S808-S814, 1997.
3. Wright AL, Holberg CJ, Martinez FD, et al. Epidemiology of physicians - diagnosed allergic rhinitis in childhood. Pediatrics 94:895-901, 1994.
4. Kay AB. Allergy and allergic diseases. N Engl J Med 344:30-37, 2001.
5. Naclerio RM. Allergic rhinitis. N Engl J Med 325:860-869, 1991.
6. Simon RA. The allergy asthma connection. Allergy Asthma Proc 23:219-222, 2002.
7. Du Buske LM. Mediator antagonists in the treatment of allergic disease. Allergy Asthma Proc 22:261-275, 2001.
8. Bousquet J, Vignola AM, Campbell AM, et al. Pathophysiology of allergic rhinitis. Arch Allergy Immunol 110:207-218, 1996.
9. Busse WW, Calhoun WF, and Sedgwick JD. Mechanism of airway inflammation in asthma. Am Rev Respir Dis 147:S20-S24, 1993.
10. Grossman J. One airway, one disease. Chest 111:S11-S16, 1997.
11. Holgate ST, Bradding P, and Sampson AP. Leukotriene antagonists and synthesis inhibitor: new directions in asthma therapy. J Allergy Clin Immunol 98:1-13, 1996.
12. Togias A. Mechanisms of nose-lung interaction. Allergy 54:94-105, 1999.
13. Corren J, Adinoff AD, and Irvin CG. Changes in bronchial responsiveness following nasal provocation with allergen. J Allergy Clin Immunol 89:611-618, 1992.
14. Braunstahl GJ, Kleinjan A, Overbeek SE, et al. Segmental bronchial provocation induces nasal inflammation in allergic rhinitis patients. Am J Repir Crit Care Med 161:2051-2057, 2000.
15. Gaga M, Lambrou P, Papageorgiou N, et al. Eosinophils are a feature of upper and lower airway pathology in non-atopic asthma, irrespective of the presence of rhinitis. Clin Exp Allergy 30:663-669, 2000.
16. Dela Fuene G, Lin J, and Frieri M. Immunohistologic analysis in autopsy specimens from asthma patients. J Allergy Clin Immunol 99:167a, 1997.
17. Hacena M, Zitt M, and Frieri M. A prospective outcome study in patients with asthma on inhaled corticosteroid treatment. Ann Allergy Asthma Immunol 86:38a, 2001.
18. Frieri M, Therattil J, Dellavecchia D, et al. A preliminary retrospective treatment and pharmacoecomic analysis of asthma care provided by allergists, immunologists, and primary care physicians in a teaching hospital. J. Asthma 39:405-412, 2002.
19. Blaiss MS. Medical and economic dimensions linking allergic rhinitis and asthma. Allergy Asthma Proc 23:223-227, 2002.
20. Simons FER. Allergic rhino-bronchitis: the asthma-allergic rhinitis link. J Allergy Clin Immunol 104:534-540, 1999.
21. Togias A. Unique mechanistic features of allergic rhinitis. J Allergy Clin Immunol 105:S599-S604, 2000.
22. Fireman P. Rhinitis and asthma connection: management of coexisting upper airway allergic diseases and asthma. Allergy Asthma Proc 21:45-54, 2000.
23. Corren J. Allergic rhinitis and asthma: how important is the link? J Allergy Clin Immunol 99:S781-S786, 1997.
24. Pedersen PA, and Week ER. Asthma and allergic rhinitis in the same patients. Allergy 38:25-29, 1983.
25. Frieri M. Allergen and environmental triggers. Emerg Med 31:73-78, 1999.
26. Corren J. The association between allergic rhinitis and asthma in children and adolescents: epidemiologic considerations. Pediatr Ann 29:400-402, 2000.
27. Schoenwetter WF. Allergic rhinitis: epidemiology and natural history. Allergy Asthma Proc 21:1-6, 2000.
28. Settipane RJ, Hagy GW, and Settipane GA. Long-term risk factors for developing asthma and allergic rhinitis: a 23 year follow-up study of college students. Allergy Proc 15:21-25, 1994.
29. Madonini E, Briatico-Vangosa G, Pappacoda A, et al. Seasonal increase of bronchial reactivity in allergic rhinitis. J Allergy Clin Immunol 79:358-363, 1987.
30. Frieri M. Nitric oxide in allergic rhinitis and asthma. Allergy Asthma Proc 19:349-351, 1998.
31. Lundberg JO. Nitric oxide in the nasal airways. Eur Respir Rev 9:241-245, 1999.
32. Lundberg JO, Lundberg JM, Settergren G. Nitric oxide produced in the upper airways may act in an P. aerocrine fashion to enhance pulmonary oxygen uptake in humans. Acta Physiol Scand 155:467-468, 1995.
33. Frieri M, Sansone G, Wang SF, et al. Mononuclear cell nitric oxide production from patients with asthma and allergic rhinitis. Ann Allergy 97:2552a, 1996.
34. Sansone G, Matin A, Wang SF, et al. Theophylline inhibits the production of nitric oxide by peripheral blood in mononuclear cells from patients with asthma. Ann Allergy Asthma Immunol 81:90-95, 1998.
35. Frieri M, Pergolizzi R, Millan C, and Dominquez PJ. Cytokine, chemokine, and nitric oxide release in stimulated small airway cells treated with β2 agonist enantiomers of albuterol. J Allergy Clin Immunol 105:858a, 2000.
36. Frieri M, Cardenas P, Moll B, et al. Effects of enoxaparin sodium on the proliferation and secretion of bronchial epithelial cells and small airway epithelial cells. J Allergy Clin Immunol 107:329a, 2001.
37. Hacena M, Moll B, Goodwin C, et al. Assessment of IL-8, TNFα, TGFβ, and nitric oxide release and expression from antigen and growth factor stimulated pulmonary epithelial cells with budesonide. J Allergy Clin Immunol 109:38a, 2002.
38. Arnal JF, Flores P, Rami J, et al. Nasal nitric oxide concentration in paranasal sinus inflammatory diseases. Eur Respir J 13:307-312, 1999.
39. Pasto M, Serrano E, Urocoste E, and Barbacanne MA. Nasal polypderived superoxide anion. Am J Respir Crit Care Med 163:145-151, 2001.
40. Shturman-Ellstein R, Zeballes RJ, Buckley JM, et al. The beneficial effect of nasal breathing on exercise-induced bronchoconstriction. Am Rev Respir Dis 118:65-73, 1978.
41. Frieri M. Corticosteroid effects on cytokines and chemokines. Allergy Asthma Proc 20:147-159, 1999.
42. Frieri M, Therattil J, Than S, et al. Montelukast inhibits IL-5 mRNA expression and cysteinyl leukotriene production in ragweed and mite stimulated mononuclear cells from asthmatics. J Allergy Clin Immunol 103:781a, 1999; Allergy Asthma Proc 24:359-366, 2003.
43. Frieri M, Therattil J, Than S, et al. Montelukast inhibits IL-5 mRNA expression and cysteinyl leukotriene production in ragweed and mite stimulated mononuclear cells from asthmatics. J Allergy Clin Immunol 103:781a, 1999; Allergy Asthma Proc 24:359-366, 2003.
44. Welsch PW, Stricker WE, Chu CP, et al. Efficacy of beclomethasone nasal solution, flunisolide, and cromolyn in relieving symptoms of ragweed allergy. Mayo Clin Proc 62:124-134, 1987.
45. Corren J, Adinoff AD, Buchmeier AD, and Irvin CG. Nasal beclomethasone prevents the seasonal increase in bronchial responsiveness in patients with allergic rhinitis and asthma. J Allergy Clin Immunol 90:250-256, 1992.
46. Henriksen JM, and Wenzel A. Effect of an intranasally administered corticosteroid budesonide or nasal obstruction, mouth breathing and asthma. Am Rev Respir Dis 130:104-1018, 1984.
47. Frieri M. Antigen-specific anti-allergic inflammatory effect of sodium cromoglycate. Is there a new cellular mechanism? Ann Allergy Asthma Immunol 83:493-494, 1999.
48. Minshall E, Ghaffar O, Cameron L, et al. Assessment by nasal biopsy of long-term use of mometasone furonate agueou nasal spray in the treatment of perennial rhinitis. Otolaryngol Head Neck Surg 118:648-654, 1998.
49. Frieri M, Therattil J, Chavarria V, et al. Effect of mometasone furoate on early and late phase inflammation in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 81:431-437, 1998.
50. Frieri M. Treatment update for allergic rhinitis. Allergy Asthma Proc 21:377-379, 2000.
51. Grant JA, Nicodemus CF, Findley ST, et al. Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol 95:923-932, 1995.
52. Bjarnsdottir U, Quan SF, and Busse WW. Essinophils and asthma. In Asthma and Rhinitis. Busse WW and Holgate ST (Eds.). Chap. 25. Boston: Blackwell Scientific Publications, 2000. pp. 328-346.
53. Day J. Pros and cons of the use of antihistamines in managing allergic rhinitis. J Allergy Clin Immunol 103:S39-S399, 1999.
54. Meltzer EO. Pharmacological treatment options for allergic rhinitis and asthma. Clin Exp Allergy 28:27-36, 1998.
55. Canonica GW, and Ciprandi G. Minimal persistent inflammation may be controlled by cetirizine. Ann Allergy Asthma Immunol 83:445-448, 1999.
56. Rachelefsky GS. Pharmacologic management of allergic rhinitis. J Allergy Clin Immunol 101:8367-8369, 1998.
57. Cuss FM. Beyond the histamine receptor: effect of antihistamines on mast cells. Clin Exp Allergy 29:54-59, 1999.
58. Frieri M, Madden J, Zitt M, et al. Late phase inflammation during nasal grass and ragweed challenge in a double-blind placebo controlled trial and astemizole. Am J Rhinol 9:1-9, 1995.
59. 4 levels. Allergy Asthma Proc 17:93-102, 1996.
60. Weldon D. Diagnosis and management of rhinitis. Prim Care 25:831-848, 1998.
61. Ciprandi G, Passalacqua G, and Canonica GW. Effects of H1 antihistamines on adhesion molecules: a possible rationale for long-term treatment. Clin Exp Allergy 29:49-53, 1999.
62. Simpson K, and Jarvis B. Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 59:301-321, 2000.
63. Markham A, and Wagstaff AJ. Fexofenadine. Drugs 55:269-274, 1998.
64. Howarth PH, Stern MA, Roi L, et al. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 104:927-933, 1999.
65. 1-receptor antagonist fexofenadine and the cysteinyl leukotriene 1-antagonist montelukast. Ann Allergy Asthma Immunol 86:44-50, 2001.
66. Abdelaziz MM, Devalia JI, Khair OA, et al. Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis. J Allergy Clin Immunol 101:410-420, 1998.
67. Hacena M, Courtney S, Muldvey L, et al. IL-8, TGFβ, and GMCSF production from ragweed and dust mite-stimulated human pulmonary epithelial cells with budesonide. Ann Allergy Asthma Immunol 90:79A, 2003.
68. Zimmermann J, Huang YC, and Frieri M. Effect of fexofenadine and budesonide in the presence of histamine on dust mite-stimulated IL-8 production from human alveolar airway epithelial cells. Presented at the SWAF/EAC/TAAIS Combined Meeting, Puerto Vallarta, Mexico, Jan 19, 2003. Allergy Asthma Proc 24:456, 2003 (Abs).
69. Zimmermann J, Huang YC, and Frieri M. Effect of fexofenadine and budesonide in the presence of histamine on dust mite-stimulated IL-8 production from human alveolar airway epithelial cells. Presented at the SWAF/EAC/TAAIS Combined Meeting, Puerto Vallarta, Mexico, Jan 19, 2003. Allergy Asthma Proc 24:456, 2003 (Abs).
70. Triggiani M, Gentile M, and Secondo A. Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors. J Immunol 266:4083, 2001.
71. Shichijo M, Inagaki N, Nakai N, et al. The effects of anti-asthma drugs on mediator release from cultured human mast cells. Clin Exp Allergy 28:1228-1236, 1998.
72. Lieberman P. Management of allergic rhinitis with a combination antihistamine/anti-inflammatory agent. J Allergy Clin Immunol 103:S400-S404, 1999.
73. McNeely W, and Wiseman LR. Intranasal azelastine: a review of its efficacy in the management of allergic rhinitis. Drugs 56:91-114, 1998.
74. Howarth PH. A comparison of the anti-inflammatory properties of intranasal corticosteroids and antihistamines in allergic rhinitis. Allergy 62:6-11, 2000.
75. Beck G, Mansur A, Afzal M, et al. Effect of azelastine nasal spray on mediators of inflammation in patients with seasonal allergic rhinitis. J Allergy Clin Immunol 105:607a, 2000.
76. Hacena M, Beck G, Afzal M, et al. A randomized double-blind, placebo controlled crossover nasal provocation study of the effect of azelastine on inflammatory mediators in SAR. Ann Allergy Asthma Immunol 88:32, 2002.
77. Corren J, Harris AG, Aaronson D, et al. Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. J Allergy Clin Immunol 100:7881-788, 1997.
78. 4-receptor antagonist, ICI 204-291, relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med 51:1734-1739, 1995.
79. Malmstrom K, Hampel FC, Philip G, et al. for the Montelukast Spring Rhinitis Investigator Group. Montelukast in the treatment of spring allergic rhinitis in a large, double-blind, randomized, placebo-controlled study. J Allergy Clin Immunol 107:S157, 2001 (Abs).
80. Meltzer EO, Malmstrom K, Lu S, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol 105:917-922, 2000.
81. Wilson AM, Orr LC, Sims EJ, and Lipwoth BJ. Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic-rhinitis. Clin Exp Allergy 31:61-68, 2001.
82. Reicin A, White R, Weinstein SF, et al. for the Montelukast/Loratadine Study Group. Montelukast, a leukotriene receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma. Arch Intern Med 160:2481-2488, 2000.
83. Nayak A, Philip G, Lu S, et al. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multi center randomized, double-blind placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol 88:592-600, 2002.
84. Philip G, Malmstrom K, Hampel FC Jr, et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind placebo-controlled trial performed in the Spring. Clin Exp Allergy 32:1020-1028, 2002.